Two-Step Cytokine Culture for NK Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural killer cells are difficult to maintain and expand while retaining their tumor-targeting and tumoricidal capabilities, making it challenging to apply them effectively in immunotherapy due to the expensive and side-effect prone LAK cell treatment methods.
Innovation Solution
A two-step method for producing activated natural killer cells by culturing hematopoietic stem or progenitor cells in a first medium with specific cytokines like IL-15 and optionally SCF and IL-7, followed by expansion in a second medium with IL-2, to produce a population of activated NK cells (TSNK cells) that retain tumoricidal functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LAK cell treatment is used to expand NK cells, then tumoricidal capability is improved, but treatment cost and side effects increase
Solution Approach 1:
The patent changes the cytokine parameters from traditional high-dose IL-2 alone to a combination of IL-15 and IL-7 in the first medium, followed by IL-2 in the second medium. This parameter change enables efficient expansion while maintaining tumoricidal capability and reducing side effects. The specific cytokine combination and concentrations are optimized to achieve the desired balance between expansion efficiency and safety.
Solution Approach 2:
The patent divides the NK cell expansion process into two distinct steps: first medium with IL-15 and IL-7 for initial expansion and differentiation, then second medium with IL-2 for further expansion and activation. This segmentation allows each step to be optimized independently, improving overall efficiency while reducing the burden of high-dose IL-2 alone.
2Reliability
If conventional NK cell expansion methods are used, then tumoricidal function is maintained, but manufacturing complexity and cost increase
Solution Approach 1:
The patent defines specific cytokine parameter combinations (IL-15 + IL-7 in first medium, then IL-2 in second medium) that simplify the manufacturing process while maintaining tumoricidal function. These parameter changes reduce the need for complex multi-cytokine formulations and extensive process optimization.
3Productivity
If hematopoietic cells are cultured in defined medium with specific cytokines, then expansion efficiency is improved, but medium complexity increases
Solution Approach 1:
The patent optimizes the medium composition by changing from undefined serum-based media to defined media with specific cytokine combinations. This parameter change improves expansion efficiency and reduces variability while keeping the medium formulation manageable through systematic cytokine selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method efficiently expands and differentiates hematopoietic cells into activated NK cells with maintained tumoricidal capabilities, offering a more effective and less costly alternative for immunotherapy with reduced side effects.
Implementation Method 1
seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7)
Implementation Method 2
expanding the cells from the first step in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells
Data Source
AI summary
Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.